Lerociclib

DB16218InvestigationalSmall molecule

Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer).

Formula / weight: C₂₆H₃₄N₈O · 474.613 g/mol (avg)
Also known as: G1t38 free base
Code names: G1T38

Resolves to

Compound

UNIIWBH8AY6ENBCAS1628256-23-4ChEMBLCHEMBL3904602

Structure

InChIKeyYPJRHEKCFKOVRT-UHFFFAOYSA-NSMILESCC(C)N1CCN(CC1)C1=CC=C(NC2=NC=C3C=C4N(C3=N2)C2(CCCCC2)CNC4=O)N=C1

Targets

Q00534CDK6P11802CDK4

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lerociclib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account